Primarily, the merger allows Mach7 access to new capital via public markets in Australia, where 3D Medical is based.
Under the terms of the agreement, 3D Medical will issue of 459.5 million shares to the owners of Mach7 in return for 100% of Mach7 assets and intellectual property. Shares will also be made available to the owners of Mach7 subject to the achievement of agreed-upon financial milestones.
In addition, 3D Medical intends to raise new funding of up to $10 million Australian ($7.3 million U.S.) to provide working capital to support further research and development, customer support, sales, and marketing activities for Mach7, as well as to build out 3D Medical's data offerings, absolve Mach7's debt (about $2 million U.S.), and pay for the cost of the merger.
Both firms plan to maintain their respective workforces in engineering, customer sales, support, marketing, and service relationships without alteration, they said. Subject to shareholder approval and upon completion of the merger, 3D Medical will change the name of the company to Mach7 Technologies and appoint Albert Liong as managing director of the group.
Copyright © 2015 AuntMinnie.com